Search results
ESCMID Presenters Make Case for Saliva Samples in Molecular Infectious Disease Testing
GenomeWeb News· 14 hours agoSaliva is a promising sample type for molecular diagnostic testing in infectious diseases beyond SARS-CoV-2, such as monkeypox and influenza ...
...WHO) Statement on the Antigen Composition of COVID-19 Vaccines - SARS-CoV-2 Continues to...
Sierra Sun Times· 3 days agoSARS-CoV-2 continues to circulate and evolve with important genetic and antigenic evolution of the spike protein. The objective of an ...
Epidemiology of SARS-CoV-2 in Kakuma Refugee Camp Complex, Kenya, 2020–2021
Centers for Disease Control and Prevention· 5 days agoThe virus spread rapidly in China and globally; the World Health Organization (WHO) declared a pandemic on March 11, 2020 (2). To contain the pandemic, many countries restricted ...
COVID-19 Proteins Can Hang Around In The Blood For Up To 14 Months After Infection
IFLScience· 2 days agoThe idea that SARS-CoV-2, the virus behind COVID-19, may be able to persist in the body long after...
Study identifies immunity threshold for protection against COVID-19 in children
Medical Xpress· 17 hours agoThe team followed up with the participants for one year, during which participants periodically donated blood to test for immune response to the vaccine: antibodies, memory ...
COVID Rash: Explaining Short- and Long-Term Symptoms
Verywell Health via Yahoo News· 19 hours agoRash and COVID-19: What’s the Link? The virus that causes COVID-19 (SARS-CoV-2) has evolved several times, and each variant has a different ...
Hologic (HOLX) to Release Quarterly Earnings on Thursday
ETF DAILY NEWS· 7 hours agoAnalysts expect the company to announce earnings of $0.98 per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link. Hologic ( ...
New diagnostic tool achieves accuracy of PCR tests with faster and simpler nanopore system
Newswise· 5 days agoIn a new paper in the journal Proceedings of the National Academy of Sciences, Schmidt...
Data: Optimal initiation of Paxlovid in hospitalized COVID patients is 3 to 5 days
Center for Infectious Disease Research and Policy· 7 days agoTaking the SARS-CoV-2 antiviral drug nirmatrelvir-ritonavir (Paxlovid) 3 to 5 days after COVID-19...
Antibiotic neomycin may protect against the flu, COVID-19
Medical News Today· 5 days agoViral respiratory infections are common and generally result in a few days of illness from which...
